Proteomic Alterations in Xenograft of Human Melanoma by Targeting Knockout of Cyclin-Dependent Kinase 2

doi:10.19894/j.issn.1000-0518.240242

Chinese Journal of Applied Chemistry ›› 2025, Vol. 42 ›› Issue (3): 345-352.DOI: 10.19894/j.issn.1000-0518.240242

• Full Papers • Previous Articles Next Articles

Proteomic Alterations in Xenograft of Human Melanoma by Targeting Knockout of Cyclin-Dependent Kinase 2

Hou-Guang LIU(), Zheng LI, Shan-Shan HUO, Qiong-Ling WEI, Hai-Mei ZHANG, Jian-Bin WU, Ya-Wen JIANG

Department of Dermatology，the Third Hospital of Xiamen，Xiamen 361100，China

Received:2024-08-01 Accepted:2025-01-31 Published:2025-03-01 Online:2025-04-11
Contact: Hou-Guang LIU
About author:liuhouguang0516@163.com
Supported by:
Fujian Provincial Health Technology Project(2021CXB027)

Abstract

Abstract:

Human melanoma is a cutaneous melanoma with high morbidity and mortality， especially for advanced malignant melanoma which pose a seriously threat to human health. Dysregulation of cell cycle of human melanoma cell is sufficient to cause human melanoma. Among the cyclin-dependent kinases （CDKs）， CDK2 plays an important role in regulation of cell cycle. However， how CDK2 regulate the proteome of human melanoma cell remains unknown. In this study， the proteomic alterations in human melanoma xenograft by targeting knockout of CDK2 were studied. The results showed that a total of 185 differentially expressed proteins （DEPs） were identified as significantly changed DEPs， 68 DEPs were down-regulated and 117 DEPs were up-regulated in CDK2 knockout （CDK2-KO） group compared with tumor group. A total of 203 DEPs were identified as significantly changed DEPs， 98 DEPs were down-regulated and 105 DEPs were up-regulated in CDK2-KO group compared with CDK2 knockout negative （CDK2-NC） group after human melanoma xenograft was infected with recombinant sgCDK2-108 lentivirus. Rps29， Adrm1， Fam162a and Rps15 were same down-regulated DEPs， Obp1b， Serpinb1a， Ttr and Slc9a3r1 were same up-regulated DEPs. These DEPs mainly referred to biological processes such as regulation of peptidase activity， regulation of endopeptidase activity， negative regulation of hydrolase activity. This study reveals the role of CDK2 in regulation network and biological function in human melanoma and provides a novel evidence for targeting CDK2 in human melanoma therapy.

Key words: Human melanoma, CDK2, Proteome, Xenograft

CLC Number:

O654.9

Hou-Guang LIU, Zheng LI, Shan-Shan HUO, Qiong-Ling WEI, Hai-Mei ZHANG, Jian-Bin WU, Ya-Wen JIANG. Proteomic Alterations in Xenograft of Human Melanoma by Targeting Knockout of Cyclin-Dependent Kinase 2[J]. Chinese Journal of Applied Chemistry, 2025, 42(3): 345-352.

Figures/Tables 7

Fig.1 Diagram of significantly proteomic alterations in human melanoma xenograft caused by CDK2 knockout

Table 1 Proteomic alterations of human melanoma xenograft after CDK2 knockout

Total peptides	Total proteins	Numbers of DEPs
Total peptides	Total proteins	CDK2-KO vs. Tumor	CDK2-KO vs. CDK2-NC
18 009	3 057	185	203

Table 2 Top 10 significantly up-regulated/down-regulated DEPs of human melanoma xenograft after CDK2 knockout

Groups	DEPs
Groups	CDK2-KO vs. Tumor	CDK2-KO vs. CDK2-NC
Down-regulated	Rps29， Vgf， Bpifa2， Adrm1， Fam162a， Rps15， Vat1l， Hspbp1， Ube3a， Tcea1	Rps29， Fam162a， Rps15， Tomm22， Eef1b2， Nedd8， Adrm1， Emc8， Cd151， Stat1
Up-regulated	Obp1b， Gpx3， Aldh3b1， Serpinb1a， Ttr， Slc9a3r1， Chi3l1， Col1a1， Apoa4， Gm5483	Obp1b， Slc9a3r1， Hmgb1， Anp32a， Ptges3， Serpinc1， Thbs2， Hapln1， Serpinb1a， Ttr

Fig.2 Protein interaction network of DEPs at CDK2-KO vs. Tumor group in human melanoma xenograft after CDK2 knockout

Fig.3 Protein interaction network of DEPs at CDK2-KO vs. CDK2-NC group in human melanoma xenograft after CDK2 knockout

Fig.4 GO analyses of DEPs at CDK2-KO vs. Tumor group in human melanoma xenograft after CDK2 knockout

Fig.5 GO analyses of DEPs at CDK2-KO vs. CDK2-NC group in human melanoma xenograft after CDK2 knockout

References 22

1	VILLANI A， SCALVENZI M， MICALI G， et al. management of advanced invasive melanoma： new strategies［J］. Adv Ther， 2023， 40（8）： 3381-3394.
2	李玲芝，石磊，朱小霞，等. 23例恶性黑色素瘤患者的临床特点及预后分析［J］. 中国现代医生， 2022， 60（31）： 39-43.
	LI L Z， SHI L， ZHU X X， et al. Clinical characteristics and prognosis analysis of 23 patients with malignant melanoma［J］. China Modern Doctor， 2022， 60（31）： 39-43.
3	张海霞，李磊，金磊，等. 云南省肿瘤医院1203例黑色素瘤临床分析［J］. 昆明医科大学学报， 2022， 43（8）： 56-60.
	ZHANG H X， LI L， JIN L， et al. Clinical features of 1203 melanoma cases in Yunnan cancer hospital［J］. J Kunming Med Univ， 2022， 43（8）： 56-60.
4	MOU H， TAN Q. Surgical research progress of sentinel lymph node biopsy in melanoma［J］. J Invest Surg， 2023， 36（1）： 2225087.
5	HUNT T， NASMYTH K， NOVAK B. The cell cycle［J］. Philos Trans R Soc Lond B Biol Sci， 2011， 366（1584）： 3494-3497.
6	ABDULLAH C， WANG X， BECKER D. Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma［J］. Cell Cycle， 2011， 10（6）： 977-988.
7	王艳娜，刘红宇，周璐青. 恶性黑色素瘤肝转移的MRI表现［J］. 浙江实用医学， 2022， 27（3）： 229-232.
	WANG Y N， LIU H Y， ZHOU L Q. MRI findings of liver metastases in malignant melanoma［J］. Zhejiang Practic Med， 2022， 27（3）： 229-232.
8	谢超群，苗秀明，宋业强. 黑色素瘤的中西医研究进展［J］. 中医临床研究， 2022， 14（6）： 99-102.
	XIE C Q， MIAO X M， SONG Y Q. Research progress of traditional Chinese medicine and western medicine treatment of melanoma［J］. Clin J Chin Med， 2022， 14（6）： 99-102.
9	李清青，李晓伟. 黑色素瘤免疫治疗耐药机制的研究进展［J］. 皮肤科学通报， 2022， 39（5）： 479-484.
	LI Q Q， LI X W. The process of resistance mechanism in melanoma immunotherapy［J］. Dermatol Bull， 2022， 39（5）： 479-484.
10	刘厚广，刘卓，姜颖，等. 腺相关病毒介导的CDK2-shRNA促进黑色素瘤细胞A375凋亡［J］. 中国地方病防治杂志， 2015， 30（2）： 135-136.
	LIU H G， LIU Z， JIANG Y， et al. Promotion apoptosis of human melanoma cells by adenovirus-associated virus mediated CDK2-shRNA［J］. Chin J Ctrl Endem Dis， 2015， 30（2）： 135-136.
11	刘厚广，刘卓，姜颖，等. 慢病毒介导的CDK2-shRNA促进黑色素瘤细胞A375凋亡［J］. 中国老年学杂志， 2015， 35（22）： 6345-6347.
	LIU H G， LIU Z， JIANG Y， et al. Promotion apoptosis of human melanoma cells by lentivirus mediated CDK2-shRNA［J］. Chin J Gerontol， 2015， 35（22）： 6345-6347.
12	BHATIA S， POOJ A， YADAV S K. CRISPR-Cas for genome editing： classification， mechanism， designing and applications［J］. Int J Biol Macromol， 2023， 238： 124054.
13	VAGHARI TABARI M， HASSANPOUR P， SADEGHSOLTANI F， et al. CRISPR/Cas9 gene editing： a new approach for overcoming drug resistance in cancer［J］. Cell Mol Biol Lett， 2022， 27（1）： 49.
14	ILYECHOVA E Y， BONALDI E， ORLOV I A， et al. CRISP-R/Cas9 mediated deletion of copper transport genes CTR1 and DMT1 in NSCLC cell Line H1299. biological and pharmacological consequences［J］. Cells， 2019， 8（4）： 322.
15	LIU H， LI Z， HUO S S， et al. Induction of G0/G1 phase arrest and apoptosis by CRISPR/Cas9-mediated knockout of CDK2 in A375 melanocytes［J］. Mol Clin Oncol， 2020， 12（1）： 9-14.
16	刘厚广，李铮，霍珊珊，等. 靶向敲除CDK2对人黑素瘤移植瘤中miRNA表达谱的影响［J］. 中国皮肤性病学杂志， 2019， 33（12）： 1354-1360.
	LIU H G， LI Z， HUO S S， et al. Changes in miRNA profile in human melanoma xenografts by CDK2 knockout［J］. Chin J Dermatovenerol， 2019， 33（12）： 1354-1360.
17	ASGHAR U， WITKIEWICZ A K， TURNER N C， et al. The history and future of targeting cyclin-dependent kinases in cancer therapy［J］. Nat Rev Drug Discov， 2015， 14（2）： 130-146.
18	TADESSE S， ANSHABO A T， PORTMAN N， et al. Targeting CDK2 in cancer： challenges and opportunities for therapy［J］. Drug Discov Today， 2020， 25（2）： 406-413.
19	YIN X， YU J， ZHOU Y， et al. Identification of CDK2 as a novel target in treatment of prostate cancer［J］. Future Oncol， 2018， 14（8）： 709-718.
20	ZHANG C， WANG X， ZHANG C. Icaritin inhibits CDK2 expression and activity to interfere with tumor progression［J］. iScience， 2022， 25（9）： 104991.
21	ZHU Y， KE K B， XIA Z K， et al. Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinoma［J］. Mol Med， 2021， 27（1）： 15.
22	YANG L， WANG M， LI B， et al. Discovery of novel CDK2 inhibitors using multistage virtual screening and in vitro melanoma cell lines［J］. FASEB J， 2023， 37（4）： e22889.

Proteomic Alterations in Xenograft of Human Melanoma by Targeting Knockout of Cyclin-Dependent Kinase 2

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 7

References 22

Related Articles 1

Recommended Articles

Metrics

Comments